Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 275-280

  Maitland, Norman J ^a   Conway, Sarah ^b   Wilkinson, Nafisa S ^b   Ramsdale, Jane ^b   Morris, Jo R ^a   Sanders, Cyril M ^a   Burns, Julie E ^a   Stern, Peter L ^c   Wells, Michael ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cervical cancer; E2 open reading frame; HPV 16

Indexed keywords

FORMALDEHYDE; PARAFFIN; POLYCLONAL ANTIBODY; TRANSCRIPTION FACTOR; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 0031727896     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998110)186:3<275::AID-PATH159>3.0.CO;2-E     Document Type: Article

References (24)

1. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994; 186: 131-156.
2. Bosch FX, Manos MM, MuOoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Nat Cancer Inst 1995; 87: 796-802.
3. Andersson-Ellstrom A, Dillner J, Hagmar B, et al. Comparison of development of serum antibodies to HPV 16 and HPV 33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls: a longitudinal cohort study. Sexually Transmitted Dis 1995; 23: 234-238.
4. Sanders CM, Stern PL, Maitland NJ. Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells. Virology 1995; 211: 418-433.
5. Ham J, Dostatni N, Gauthier J-M, Yaniv M. The papillomavirus E2 protein: a factor with many talents. TIBS 1991; 16: 440-444.
6. McBride AA, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. J Biol Chem 1991; 266: 18 411-18 414.
7. Bouvard V, Storey A, Pim D, Banks L. Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J 1994; 13: 5451-5459.
8. Ushikai M, Lace MJ, Yamakawa Y, et al. Transactivation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of cellular transcription factors. J Virol 1994; 68: 6655-6666.
9. Demeret C, Yaniv M, Thierry F. The E2 transcriptional repressor can compensate for SP1 activation of the human papillomavirus type 18 early promoter. J Virol 1994; 68: 7075-7082.
10. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995; 69: 7791-7799.
11. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997; 16: 504-514.
12. Frattini MG, Hurst SD, Lim HB, Swaminathan S, Laimins LA. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J 1997; 16: 318-331.
13. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314: 111-113.
14. Yee C, Krishnan-Hewlett I, Baker CC, et al. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985; 119: 361-366.
15. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms. J Virol 1991; 65: 606-612.
16. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989; 172: 63-72.
17. Schneider A, Oltersdorf T, Schneider V, Gissmann L. Distribution pattern of human papilloma virus 16 genome in cervical neoplasia by molecular in situ hybridization of tissue sections. Int J Cancer 1987; 39: 717-721.
18. Stoler MH, Broker TR. In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Hum Pathol 1986; 17: 1250-1258.
19. Crum CP, Nuovo G, Friedman D, Silverstein SJ. Accumulation of RNA homologous to human papillomavirus type 16 open reading frames in genital precancers. J Virol 1988; 62: 84-90.
20. Guiot M-CP, Cavenee WK, Banks L, Crawford L, Arseneau J, Matlashewski G. Immunological detection of E6 region protein from human papillomavirus types 16 and 18 in premalignant cervical lesions. Cancer Cells 1989; 7: 193-196.
21. Durst M. Glitz D, Schneider A, zur Hausen H. Human papillomavirus type 16 gene expression and DNA replication in cervical neoplasia: analysis by in xitu hybridization. Virology 1992; 189: 132-140.
22. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995; 76: 1888-1901.
23. Rocha-Zavaleta L, Jordan D, Pepper S, et al. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Br J Cancer 1997; 75: 1144-1150.
24. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical neoplasia. J Natl Cancer Inst 1995; 87: 1365-1371.